Amministrazione trasparente

Titolo della ricerca: New therapeutic option for resistant chronic myeloid leukemia patients.Progetto di ricerca: The treatment of chronic myeloid leukemia in the past 15 years has deeply changed after the introduction of tyrosine kinase inhibitors (TKIs). Although the outstanding results achieved, a fraction of patients develop resistance and the most frequent reason is the onset ABL kinase domain mutations. With second and third generation TKIs about 40-50% of resistant patients can be rescued. Asciminib is a potent, specific, orally bioavailable BCR-ABL1 inhibitor with a novel mechanism of action distinct from that of available TKIs. In contrast to binding to the ATP-site of the kinase domain, asciminib possesses an allosteric mode of action, binding a vacant pocket on the kinase domain normally occupied by ABL1’s myristoylated N-terminus peptide. Aim of this project is to prospectively collect clinical and biological data of resistant/intolerant patients in every phase of disease that will be treated with this new agent in phase 1a and subsequent planned phase 2 trials.